Enlivex Therapeutics Ltd
NASDAQ:ENLV
Enlivex Therapeutics Ltd
Cash from Financing Activities
Enlivex Therapeutics Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash from Financing Activities
$360k
|
CAGR 3-Years
-78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cash from Financing Activities
$1.1m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Financing Activities
$22.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Financing Activities
$116.9m
|
CAGR 3-Years
92%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Financing Activities
$6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cash from Financing Activities
-₪1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Enlivex Therapeutics Ltd's Cash from Financing Activities?
Cash from Financing Activities
360k
USD
Based on the financial report for Dec 31, 2023, Enlivex Therapeutics Ltd's Cash from Financing Activities amounts to 360k USD.
What is Enlivex Therapeutics Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-78%
Over the last year, the Cash from Financing Activities growth was 140%. The average annual Cash from Financing Activities growth rates for Enlivex Therapeutics Ltd have been -78% over the past three years .